Published 14 April 2009, doi:10.1136/bmj.b1180
Cite this as: BMJ 2009;338:b1180

Clinical Review

Clopidogrel in acute coronary syndromes

¹ St Paul’s Hospital, Department of Pharmacy, Vancouver, BC V6Z 1Y6, Canada

The first 150 words of the full text of this article appear below.

All patients presenting with acute coronary syndromes should be given a 300 mg loading dose of clopidogrel, then 75 mg daily Patients not undergoing percutaneous coronary intervention should receive clopidogrel for nine to 12 months for non-ST elevation myocardial infarction and 14 days for ST elevation myocardial infarction Patients given a bare metal stent should receive clopidogrel, in addition to aspirin, for at least one month and ideally for one year Patients given a drug eluting stent should receive clopidogrel, in addition to aspirin, for at least one year The duration of clopidogrel treatment must take into account the patient’s risk of bleeding

Clopidogrel is well established in the treatment of acute coronary syndromes and is ubiquitous in cardiology practice. Landmark studies have established the importance of clopidogrel in the treatment of non-ST and ST elevation myocardial infarction and in percutaneous coronary intervention by reducing death, reinfarction, and adverse cardiac . . . [Full text of this article]

Recommendations
Evidence

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Bleeding and resistance

Jonathan Ball
BMJ 2009 338: b1927. [Extract] [Full Text]

Increasing concordance

Peter D Burrill
BMJ 2009 338: b1928. [Extract] [Full Text]

More on proton pump inhibitors

Gareth J Sadler and Andrew P Poullis
BMJ 2009 338: b1931. [Extract] [Full Text]

Patients with peptic ulcers

Ian L Beales
BMJ 2009 338: b1932. [Extract] [Full Text]

Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction

Ever D Grech and David R Ramsdale
BMJ 2003 326: 1259-1261. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Ball, J. (2009). Bleeding and resistance. BMJ 338: b1927-b1927 [Full text]  
• Burrill, P. D (2009). Increasing concordance. BMJ 338: b1928-b1928 [Full text]  
• Sadler, G. J, Poullis, A. P (2009). More on proton pump inhibitors. BMJ 338: b1931-b1931 [Full text]  
• Beales, I. L (2009). Patients with peptic ulcers. BMJ 338: b1932-b1932 [Full text]  

Rapid Responses:

Read all Rapid Responses

NNTs and NNHs, and PPIs and H2RAs

Peter D Burrill
bmj.com, 16 Apr 2009 [Full text]

Re: NNTs and NNHs, and PPIs and H2RAs

L Sam Lewis
bmj.com, 17 Apr 2009 [Full text]

PPIs may differ in effects

Ian L.. Beales
bmj.com, 28 Apr 2009 [Full text]

Vital missing information

Jonathan Ball
bmj.com, 28 Apr 2009 [Full text]

Bleeding clopidogrel!

Gareth J Sadler, et al.
bmj.com, 5 May 2009 [Full text]

Authors' reply

Doson Chua, et al.
bmj.com, 20 May 2009 [Full text]

Online poll

Find out more here>> and here>>